UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.712

Sortiert nach

The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study

Journal of acquired immune deficiency syndromes (1999), 2010-03, Vol.53 (3), p.369

2010

Link zum Volltext

Verfügbarkeit prüfen

Is it time to retire efavirenz as a first-line option worldwide?

AIDS (London), 2022-02, Vol.36 (2), p.317-318

2022

Link zum Volltext

Verfügbarkeit prüfen

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

The Lancet infectious diseases, 2016-05, Vol.16 (5), p.565-575

2016

Link zum Volltext

Verfügbarkeit prüfen

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

The Lancet (British edition), 2011-07, Vol.378 (9787), p.229-237

2011

Link zum Volltext

Verfügbarkeit prüfen

Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer

Journal of controlled release, 2018-12, Vol.291, p.184-195

2018

Link zum Volltext

Verfügbarkeit prüfen

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

The Lancet (British edition), 2011-07, Vol.378 (9787), p.238-246

2011

Link zum Volltext

Verfügbarkeit prüfen

Efavirenz and the CNS: what we already know and questions that need to be answered

Journal of antimicrobial chemotherapy, 2015-10, Vol.70 (10), p.2693-2708

2015

Link zum Volltext

Verfügbarkeit prüfen

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK

Journal of acquired immune deficiency syndromes (1999), 2013-05, Vol.63 (1), p.77

2013

Link zum Volltext

Verfügbarkeit prüfen

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals

Cochrane database of systematic reviews, 2016-12, Vol.12 (12), p.CD004246

2016

Link zum Volltext

Verfügbarkeit prüfen

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study

The Lancet global health, 2018-07, Vol.6 (7), p.e804-e810

2018

Link zum Volltext

Verfügbarkeit prüfen

Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin

Antimicrobial agents and chemotherapy, 2023-11, Vol.67 (11), p.e0043123

2023

Link zum Volltext

Verfügbarkeit prüfen

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1

Annals of internal medicine, 2011-04, Vol.154 (7), p.445

2011

Link zum Volltext

Verfügbarkeit prüfen

Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor‑γ (RORγ) Agonist for Use in Treating Cancer

Journal of medicinal chemistry, 2021-09, Vol.64 (18), p.13410-13428

2021

Link zum Volltext

Verfügbarkeit prüfen

Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention

Clinical infectious diseases, 2015-10, Vol.61 (8), p.1322-1327

2015

Link zum Volltext

Verfügbarkeit prüfen

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

The New England journal of medicine, 2021-12, Vol.385 (27), p.2531-2543

2021

Link zum Volltext

Verfügbarkeit prüfen

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects

Antimicrobial agents and chemotherapy, 2016-10, Vol.60 (10), p.5976-5985

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study

Antimicrobial agents and chemotherapy, 2024-04, Vol.68 (4), p.e0166823

2024

Link zum Volltext

Verfügbarkeit prüfen

Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG

Clinical infectious diseases, 2023-04, Vol.76 (8), p.1492-1495

2023

Link zum Volltext

Verfügbarkeit prüfen

Class-Sparing Regimens for Initial Treatment of HIV-1 Infection

The New England journal of medicine, 2008-05, Vol.358 (20), p.2095-2106

2008

Link zum Volltext

Verfügbarkeit prüfen

Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model

British journal of pharmacology, 2016-01, Vol.173 (1), p.77-87

2016

Link zum Volltext

Verfügbarkeit prüfen

Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects

European journal of pharmacology, 2017-10, Vol.812, p.163-173

2017

Link zum Volltext

Verfügbarkeit prüfen

Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-tropic HIV-1 Infection

The Journal of infectious diseases, 2010-03, Vol.201 (6), p.803-813

2010

Link zum Volltext

Verfügbarkeit prüfen

Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

Antimicrobial Agents and Chemotherapy, 2013-06, Vol.57 (6), p.2780-2787

2013

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Clinical pharmacokinetics, 2016-07, Vol.55 (7), p.861-873

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.712

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.485)
Mit Volltextzugriff
(1.215)

Publikationsform

Sprache

7 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(1.527)
Science & Technology
(1.327)
Life Sciences & Biomedicine
(1.275)
Hiv Infections - Drug Therapy
(1.234)
Male
(986)
Benzoxazines - Therapeutic Use
(957)
Anti-Hiv Agents - Therapeutic Use
(940)
Female
(889)
Infectious Diseases
(767)
Adult
(737)
Benzoxazines
(639)
Reverse Transcriptase Inhibitors - Therapeutic Use
(613)
Hiv
(540)
Biological And Medical Sciences
(534)
Medical Sciences
(524)
Human Immunodeficiency Virus
(510)
Oxazines - Therapeutic Use
(497)
Efavirenz
(452)
Middle Aged
(438)
Pharmacology & Pharmacy
(417)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study

Is it time to retire efavirenz as a first-line option worldwide?

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

Efavirenz and the CNS: what we already know and questions that need to be answered

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study

Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1

Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor‑γ (RORγ) Agonist for Use in Treating Cancer

Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects

Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study

Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG

Class-Sparing Regimens for Initial Treatment of HIV-1 Infection

Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model

Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects

Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-tropic HIV-1 Infection

Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study

Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Suchergebnisse filtern